Category Archives: Oncology

anti-PD1 and anti-PD-L1 drugs treating NSCLC

March 26, 2013 Interviewed By Steven E. Greer, MD

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

The Damon Runyon Cancer Research Foundation panel

March 8, 2013  By Steven E. Greer, MD We interviewed three of the oncologists and industry executives who spoke at the Damon Runyon

Posted in - Biotech, - Pharma, Harvard, Oncology | Leave a comment

Bending the cost curve of cancer care

May 25, 2011- Since the approval of Genentech’s costly Avastin in 2004, prominent oncologists have warned that

Posted in - Biotech, - Pharma, CMS, Oncology, VCU | Leave a comment

Steven E. Greer MD: A discussion with Bill O’Reilly about radiation risks

April 1, 2011- A discussion with Bill O’Reilly about radiation risks from the Fukushima nuclear meltdowns and the fallout hitting the U.S. and entire globe.

Posted in - Policy, Congress, NYU, Ohio State, Oncology | Leave a comment

Paul Richardson, MD: Three-drug regimen for multiple myeloma

December 15, 2015 Dr. Paul Richardson of Harvard’s Dana-Farber Cancer Institute reviews the recent Lancet article

Posted in - Biotech, - Pharma, Harvard, Oncology | Leave a comment

Paul Richardson, MD: Current Therapies for Multiple Myeloma

December 15, 2015- Interviewed by Steven Greer, MD Dr. Paul Richardson, Clinical Director of the Multiple Myeloma Center at Harvard’s Dana-Farber

Posted in - Biotech, - Pharma, Harvard, Oncology | Leave a comment

Early palliative care improves outcomes in lung cancer patients

August 30, 2010- Produced and interviewed by Steven Greer, MD A group from Harvard published a paper in The NEJM that showed early initiation of palliative

Posted in Harvard, Oncology | Leave a comment

The unsustainable cost of cancer drugs

June 8, 2009- Interviewed by Steven Greer, MD Leonard Saltz, MD, of Memorial Sloan-Kettering Cancer Center, discusses how the targeted

Posted in - Opinion, - Policy, Congress, Memorial Sloan-Kettering, Oncology | Leave a comment